(Reuters) – Britain’s medicines regulator on Friday approved Novavax’s COVID-19 vaccine for children aged between 12 and 17 years.
The mRNA vaccines made by Moderna as well as the partnership between Pfizer-BioNTech are also cleared for use by this age group, the Medicines and Healthcare products Regulatory Agency (MHRA) said.
Britain in February cleared Novavax’s two-dose vaccine, Nuvaxovid, for use in adults.
(Reporting by Sinchita Mitra in Bengaluru; editing by Krishna Chandra Eluri and Jason Neely)
